News & Events

图片名称
图片名称

CHULA ATMP Symposium

Date : 2026-03-23

Publisher : Cytoniche | Marketing

March 30, 2026 | Bangkok, Thailand

CHULA ATMP Symposium

March 30, 2026 | Bangkok, Thailand

Exhibit Hall | Booth 15

CytoNiche Biotech successfully concluded its participation at the CHULA ATMP Symposium 2026, held on 30 March 2026 at King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

The symposium served as a valuable platform for cross-sector dialogue, bringing together researchers, clinicians, and industry leaders to explore the evolving landscape of Advanced Therapy Medicinal Products (ATMPs). Key discussions highlighted a shared industry focus on scalability, standardisation, and manufacturability—critical challenges as cell and gene therapies move closer to widespread clinical adoption.

At Booth 15, CytoNiche, together with its local distributor Prima Scientific, engaged with stakeholders across academia and industry. Conversations centred on practical approaches to addressing manufacturing bottlenecks, particularly in achieving consistent, scalable, and cost-effective cell production.

The team showcased its 3D cell manufacturing solutions, including their core 3D TableTrix™ Microcarriers and 3D FloTrix™ platform, which are designed to support:

  • Scalable expansion of adherent cells
  • Improved process consistency
  • Simplified downstream processing

These interactions reinforced the growing need for integrated, bioprocess-oriented solutions that can bridge early-stage research and clinical-scale manufacturing.

Beyond technology, the event underscored the importance of regional collaboration in Asia’s rapidly expanding ATMP ecosystem, where partnerships between technology providers, clinical institutions, and manufacturers will be key to accelerating translation.

CytoNiche extends its sincere appreciation to all visitors, partners, and organisers for the engaging discussions and insights shared. The company looks forward to building on these connections and continuing to support the advancement of scalable cell therapy manufacturing.